gebasaxturev
Term · Oncology and biomedicine · MLC-T-ONC-013916
A preparation of naturally occurring, oncolytic enterovirus, with potential antineoplastic activity. Upon administration, gebasaxturev targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are overexpressed on certain malignant cells. After entering the cells, gebasaxturev replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth.
| Identifier | MLC-T-ONC-013916 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | CVA21 |
| Synonyms | coxsackievirus A21; coxsackievirus V937 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013916",
"term": "gebasaxturev",
"field": "Oncology and biomedicine",
"definition": "A preparation of naturally occurring, oncolytic enterovirus, with potential antineoplastic activity. Upon administration, gebasaxturev targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are overexpressed on certain malignant cells. After entering the cells, gebasaxturev replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth.",
"abbreviation": "CVA21",
"synonyms": [
"coxsackievirus A21",
"coxsackievirus V937"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/gebasaxturev/"
}
Record 7,857 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.